Hemocromatose

Haute Autorité de Santé (France). Management of patients with HFE-related haemochromatosis (type 1 haemochromatosis). Jul 2005 [internet publication].Texto completo

Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.Texto completo  Resumo

European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. J Hepatol. 2022 Aug;77(2):479-502.Texto completo  Resumo

Haute Autorité de Santé (France). Management of patients with HFE-related haemochromatosis (type 1 haemochromatosis). Jul 2005 [internet publication].Texto completo

Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Jul;54(1):328-43.Texto completo  Resumo

Fitzsimons EJ, Cullis JO, Thomas DW, et al. Diagnosis and therapy of genetic haemochromatosis (review and 2017 update). Br J Haematol. 2018 May;181(3):293-303.Texto completo  Resumo

1. McCune CA, Ravine D, Carter K, et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut. 2006 Apr;55(4):554-62. Resumo

2. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999 Sep 2;341(10):718-24. Resumo

3. Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006 Aug 1;145(3):209-23. Resumo

4. Kowdley KV, Brown KE, Ahn J, et al. Correction: ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Dec;114(12):1927. Resumo

5. Girelli D, Busti F, Brissot P, et al. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood. 2022 May 19;139(20):3018-29.Texto completo  Resumo

6. Haute Autorité de Santé (France). Management of patients with HFE-related haemochromatosis (type 1 haemochromatosis). Jul 2005 [internet publication].Texto completo

7. Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.Texto completo  Resumo

8. European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. J Hepatol. 2022 Aug;77(2):479-502.Texto completo  Resumo

9. Olynyk JK, Ramm GA. Hemochromatosis. N Engl J Med. 2022 Dec 8;387(23):2159-70. Resumo

10. Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016 Aug 13;388(10045):706-16. Resumo

11. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005 Apr 28;352(17):1769-78.Texto completo  Resumo

12. Pérez R, Toro D, Fournier J, et al. Prevalence of hemochromatosis in the Puerto Rico veteran population. P R Health Sci J. 2007 Jun;26(2):147-50. Resumo

13. Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta. 2006 Jul;1763(7):700-10. Resumo

14. Terzić R, Sehić A, Teran N, et al. Frequency of HFE gene mutations C282Y and H63D in Bosnia and Herzegovina. Coll Antropol. 2006 Sep;30(3):555-7. Resumo

15. Cimburova M, Putova I, Provaznikova H, et al. S65C and other mutations in the haemochromatosis gene in the Czech population. Folia Biol (Praha). 2005;51(6):172-6.Texto completo  Resumo

16. Leone PE, Giménez P, Collantes JC, et al. Analysis of HFE gene mutations (C282Y, H63D, and S65C) in the Ecuadorian population. Ann Hematol. 2005 Feb;84(2):103-5. Resumo

17. Scotet V, Le Gac G, Mérour MC, et al. Impact of HFE genetic testing on clinical presentation of hereditary hemochromatosis: new epidemiological data. BMC Med Genet. 2005 Jun 1;6:24.Texto completo  Resumo

18. Pardo A, Quintero E, Barrios Y, et al. Genotype and phenotypic expression of hereditary hemochromatosis in Spain [in Spanish]. Gastroenterol Hepatol 2004 Oct;27(8):437-43. Resumo

19. Sassi R, Hmida S, Kaabi H, et al. Prevalence of C282Y and H63D mutations in the haemochromatosis (HFE) gene in Tunisian population. Ann Genet. 2004 Oct-Dec;47(4):325-30. Resumo

20. Wrede CE, Hutzler S, Bollheimer LC, et al. Correlation between iron status and genetic hemochromatosis (codon C282Y) in a large German population. Isr Med Assoc J. 2004 Jan;6(1):30-33.Texto completo  Resumo

21. Milman N, Pedersen P, Steig T, et al. Frequencies of the hereditary hemochromatosis allele in different populations: comparison of previous phenotypic methods and novel genotypic methods. Int J Hematol. 2003 Jan;77(1):48-54. Resumo

22. Anderson GJ, Bardou-Jacquet E. Revisiting hemochromatosis: genetic vs. phenotypic manifestations. Ann Transl Med. 2021 Apr;9(8):731.Texto completo  Resumo

23. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008 Jan 17;358(3):221-30.Texto completo  Resumo

24. Hagström H, Ndegwa N, Jalmeus M, et al. Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers. Liver Int. 2021 Mar;41(3):545-53.Texto completo  Resumo

25. National Institutes of Health. HFE homeostatic iron regulator [homo sapiens (human)]. ​Dec 2023 [internet publication].Texto completo

26. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996 Aug;13(4):399-408. Resumo

27. Gurrin LC, Bertalli NA, Dalton GW, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology. 2009 Jul;50(1):94-101.Texto completo  Resumo

28. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002 Jan 19;359(9302):211-8. Resumo

29. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998 Oct;115(4):929-36. Resumo

30. Beaton M, Guyader D, Deugnier Y, et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology. 2002 Sep;36(3):673-8. Resumo

31. Allen KJ, Bertalli NA, Osborne NJ, et al; HealthIron Study Investigators. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology. 2010 Sep;52(3):925-33.Texto completo  Resumo

32. Rossi E, Bulsara MK, Olynyk JK, et al. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem. 2001 Feb;47(2):202-8.Texto completo  Resumo

33. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003 Feb 22;361(9358):669-73. Resumo

34. Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006 Aug;44(2):472-7.Texto completo  Resumo

35. Dymock IW, Hamilton EB, Laws JW, et al. Arthropathy of haemochromatosis: clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis. 1970 Sep;29(5):469-76.Texto completo  Resumo

36. Valenti L, Fracanzani AL, Rossi V, et al. The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. J Rheumatol. 2008 Jan;35(1):153-8. Resumo

37. Harty LC, Lai D, Connor S, et al. Prevalence and progress of joint symptoms in hereditary hemochromatosis and symptomatic response to venesection. J Clin Rheumatol. 2011 Jun;17(4):220-2. Resumo

38. Potekhina ES, Lavrov AV, Samokhodskaya LM, et al. Unique genetic profile of hereditary hemochromatosis in Russians: high frequency of C282Y mutation in population, but not in patients. Blood Cells Mol Dis. 2005 Sep-Oct;35(2):182-8. Resumo

39. Adams PC, Reboussin DM, Press RD, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med. 2007 Nov;120(11):999.e1-7.Texto completo  Resumo

40. Cullis JO, Fitzsimons EJ, Griffiths WJ, et al. Investigation and management of a raised serum ferritin. Br J Haematol. 2018 May;181(3):331-40.Texto completo  Resumo

41. Gandon Y, Olivié D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004 Jan 31;363(9406):357-62. Resumo

42. Adams PC, Speechley M, Barton JC, et al. Probability of C282Y homozygosity decreases as liver transaminase activities increase in participants with hyperferritinemia in the hemochromatosis and iron overload screening study. Hepatology. 2012 Jun;55(6):1722-6.Texto completo  Resumo

43. Beaton M, Adams PC. Assessment of silent liver fibrosis in hemochromatosis C282Y homozygotes with normal transaminase levels. Clin Gastroenterol Hepatol. 2008 Jun;6(6):713-4.Texto completo  Resumo

44. Cherfane CE, Hollenbeck RD, Go J, et al. Hereditary hemochromatosis: missed diagnosis or misdiagnosis? Am J Med. 2013 Nov;126(11):1010-5. Resumo

45. Eschewege E, Saddi R, Wacjman H, et al. Haemoglobin AIc in patients on venesection therapy for haemochromatosis [in French]. Diabetes Metab. 1982 Jun;8(2):137-40. Resumo

46. Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis: current concepts and progress. Am J Med. 2006 May;119(5):391-9. Resumo

47. McDermott JH, Walsh CH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metabol. 2005 Apr;90(4):2451-5.Texto completo  Resumo

48. Valenti L, Varenna M, Fracanzani AL, et al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009 Apr;20(4):549-55. Resumo

49. Mehrany K, Drage LA, Brandhagen DJ, et al. Association of porphyria cutanea tarda with hereditary hemochromatosis. J Am Acad Dermatol. 2004 Aug;51(2):205-11. Resumo

50. Corradini E, Pietrangelo A. Iron and steatohepatitis. J Gastroenterol Hepatol. 2012 Mar;27(suppl 2):42-6. Resumo

51. Moirand R, Mortaji AM, Loréal O, et al. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 1997 Jan 11;349(9045):95-7. Resumo

52. Haute Autorité de Santé (France). Management of patients with HFE-related haemochromatosis (type 1 haemochromatosis). Jul 2005 [internet publication].Texto completo

53. Olynyk JK, Hagan SE, Cullen DJ, et al. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc. 2004 Mar;79(3):309-13. Resumo

54. Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004 Apr 15;103(8):2914-9.Texto completo  Resumo

55. Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Jul;54(1):328-43.Texto completo  Resumo

56. Fitzsimons EJ, Cullis JO, Thomas DW, et al. Diagnosis and therapy of genetic haemochromatosis (review and 2017 update). Br J Haematol. 2018 May;181(3):293-303.Texto completo  Resumo

57. Gurrin LC, Osborne NJ, Constantine CC, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology. 2008 Dec;135(6):1945-52.Texto completo  Resumo

58. McDonnell SM, Grindon AJ, Preston BL, et al. A survey of phlebotomy among persons with hemochromatosis. Transfusion. 1999 Jun;39(6):651-6. Resumo

59. Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of hepatitis A virus infection in the United States: recommendations of the advisory committee on immunization practices, 2020. MMWR Recomm Rep. 2020 Jul 3;69(5):1-38.Texto completo  Resumo

60. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 1;71(13):477-83.Texto completo  Resumo

61. Moretti D, van Doorn GM, Swinkels DW, et al. Relevance of dietary iron intake and bioavailability in the management of HFE hemochromatosis: a systematic review. Am J Clin Nutr. 2013 Aug;98(2):468-79.Texto completo  Resumo

62. Phatak P, Brissot P, Wurster M, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010 Nov;52(5):1671-9.Texto completo  Resumo

63. Cançado R, Melo MR, de Moraes Bastos R, et al. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr phase 2 study. Eur J Haematol. 2015 Dec;95(6):545-50. Resumo

64. Brissot P, Pietrangelo A, Adams PC, et al. Haemochromatosis. Nat Rev Dis Primers. 2018 Apr 5;4:18016.Texto completo  Resumo

65. Liu J, Sun B, Yin H, et al. Hepcidin: a promising therapeutic target for iron disorders: a systematic review. Medicine (Baltimore). 2016 Apr;95(14):e3150.Texto completo  Resumo

66. Vyoral D, Jiri Petrak. Therapeutic potential of hepcidin - the master regulator of iron metabolism. Pharmacol Res. 2017 Jan;115:242-54. Resumo

67. Niederau C, Fischer R, Pürschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996 Apr;110(4):1107-19. Resumo

68. van Bokhoven MA, van Deursen CT, Swinkels DW. Diagnosis and management of hereditary haemochromatosis. BMJ. 2011 Jan 19;342:c7251.Texto completo  Resumo

69. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001 Oct;36(10):1108-15.Texto completo  Resumo

70. Ellervik C, Birgens H, Tybjaerg-Hansen A, et al. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology. 2007 Oct;46(4):1071-80.Texto completo  Resumo

71. Pilling LC, Tamosauskaite J, Jones G, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank. BMJ. 2019 Jan 16;364:k5222.Texto completo  Resumo

72. Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010 Apr;51(4):1311-8.Texto completo  Resumo

73. Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci. 1988;526:245-57. Resumo

74. Bardou-Jacquet E, Morcet J, Manet G, et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol. 2015 Mar;62(3):682-9. Resumo

75. Lymberopoulos P, Prakash S, Shaikh A, et al. Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. Liver Transpl. 2023 Jan 1;29(1):15-25.Texto completo  Resumo

76. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 suppl 1):S79-86. Resumo

77. Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporosis Int. 2005 Dec;16(12):1809-14. Resumo

78. Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis. 2007 Nov;11(6):482-7.Texto completo  Resumo

79. Adams PC. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet. 1998 Mar;53(3):176-8. Resumo